首页> 美国卫生研究院文献>Iranian Journal of Medical Sciences >The Study of DNA Methyltransferase-3B Promoter Variant Genotype among Iranian Sporadic Breast Cancer Patients
【2h】

The Study of DNA Methyltransferase-3B Promoter Variant Genotype among Iranian Sporadic Breast Cancer Patients

机译:伊朗零星乳腺癌患者DNA甲基转移酶3B启动子变异基因型的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: DNA methyltransferase-3B (DNMT3B) is an important enzyme responsible for maintaining the DNA methylation pattern in eukaryotic cells. In this study we have investigated the correlation between the 46359C→T polymorphism in the DNMT3B gene and the risk of breast cancer incidence among sporadic breast cancer patients in Fars Province, Southern Iran. >Methods: In this case-control study, 100 breast cancer patients and 138 healthy control subjects were genotyped for the DNMT3B gene by the polymerase chain reaction-restriction fragment length polymorphism method. >Results: The genotype frequency in the case (CC 27%, CT 47%, TT 26%) group significantly (P=0.008) differed from the control (CC 19.56%, CT 67.3%, TT 13%) group. We observed a decreased association between the CT genotype and lymph node involvement in breast cancer patients. Our results have shown that in comparison to the homozygous CC genotype carriers the DNMT3B-CT genotype has a significantly lower risk for breast cancer (OR=0.515, 95% CI=0.267-0.994, P=0.048). >Conclusion: Our case-control study showed that the CT genotype was significantly associated with decreased breast cancer risk. Consistent with these results, a significant decrease of CT genotype among lymph node positive breast cancer patients was observed. However, a larger study population with more clinical data is needed to confirm these results.
机译:>背景: DNA甲基转移酶3B(DNMT3B)是一种重要的酶,负责维持真核细胞中的DNA甲基化模式。在这项研究中,我们调查了伊朗南部Fars省散发性乳腺癌患者中DNMT3B基因46359C→T多态性与乳腺癌发生风险之间的相关性。 >方法:在本病例对照研究中,通过聚合酶链反应-限制性片段长度多态性方法对100例乳腺癌患者和138例健康对照者的DNMT3B基因进行了基因分型。 >结果:病例组(CC 27%,CT 47%,TT 26%)的基因型频率(P = 0.008)与对照组(CC 19.56%,CT 67.3%,TT 13)显着不同%)组。我们观察到乳腺癌患者CT基因型与淋巴结受累之间的关联性降低。我们的结果表明,与纯合CC基因型携带者相比,DNMT3B-CT基因型患乳腺癌的风险显着降低(OR = 0.515,95%CI = 0.267-0.994,P = 0.048)。 >结论:我们的病例对照研究表明,CT基因型与降低乳腺癌风险显着相关。与这些结果一致,在淋巴结阳性乳腺癌患者中观察到CT基因型显着降低。然而,需要更多的具有更多临床数据的研究人群来证实这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号